American College of Clinical Pharmacy
      Search      Cart


NIH Panel Releases New Statement on Therapies for High-Risk, Non-Hospitalized Patients

January 20, 2022

The COVID-19 Treatment Guidelines Panel (the Panel) has added a new statement to the Coronavirus Disease 2019 (COVID-19) Treatment Guidelines.

Because the anti-SARS-CoV-2 monoclonal antibodies (mAbs) bamlanivimab plus etesevimab and casirivimab plus imdevimab are predicted to have markedly reduced activities against the Omicron variant, and because real-time testing to identify rare, non-Omicron variants is not routinely available, the Panel recommends against the use of these anti-SARS-CoV-2 mAbs.

For complete details, please see the full update on the COVID-19 Treatment Guidelines website.


This website uses cookies to help ACCP provide you with the best user experience. If you continue to use our services, ACCP will assume that you agree to the use of such cookies. You can find out how to update your settings by referring to ACCP’s Policy on Cookies.